US3441741077 - Common Stock
FOGHORN THERAPEUTICS INC
NASDAQ:FHTX (4/26/2024, 2:40:50 PM)
5.39
+0.16 (+3.06%)
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 161 full-time employees. The company went IPO on 2020-10-23. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The firm is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. The company is also developing FHD-609, a targeted protein degrader, and which is evaluating in a Phase I study in synovial sarcoma.
FOGHORN THERAPEUTICS INC
500 Technology Square, Suite 700
Cambridge MASSACHUSETTS 02139
P: 16175863100
CEO: Adrian Gottschalk
Employees: 161
Website: https://foghorntx.com/
CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
First-in class BRM (SMARCA2) selective inhibitor FHD-909 demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated...
Company presentation and fireside chat on April 11th at 11:45 a.m. ET
Here you can normally see the latest stock twits on FHTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: